From PRWeb The FSHD Society announced today that it has signed a memorandum of understanding to enter into a three-year agreement to enable the expansion of the international facioscapulohumeral muscular dystrophy… Read More »
FSHD Society signs agreement to expand CTRN
Charis Himeda talks about CRISPR and FSHD
From the FSHD Society’s webinar series on facioscapulohumeral muscular dystrophy. Charis Himeda, PhD, of the University of Nevada Reno, discusses her groundbreaking work showing how CRISPR “gene editing” technology can… Read More »
Fulcrum Announces Initiation of ReDUX4, a Phase 2b Clinical Trial of Losmapimod for FSHD
August 19, 2019 at 7:00 AM EDT From Fulcrum press release. PDF Version CAMBRIDGE, Mass., Aug. 19, 2019 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving… Read More »
The disappearing bomb
How DUX4 could cause FSHD without actually being there BY AMANDA HILL, HIGHLANDS RANCH, COLORADO In the FSHD research field, there is an emerging idea that the damage caused by… Read More »
A new way to detect DUX4
by Gholamhossein Amini Chermahini, MD, Columbus, Ohio Editor’s Note: Dr. Amini Chermahini and his colleagues were awarded the Best Poster Prize at this year’s FSHD International Research Congress. Here he… Read More »